Eficacia y seguimiento en el largo plazo de pacientes con psoriasis vulgar moderada a severa en tratamiento con infliximab (Remicade®) / Efficacy of infliximab in patients with moderate and severe psoriasis treated with infliximab (Remicade®)
Rev. méd. Chile
; 134(3): 326-331, mar. 2006. tab, graf
Article
em Es
| LILACS
| ID: lil-426099
Biblioteca responsável:
BR1.1
ABSTRACT
Background:
Psoriasis has a moderate or severe course in 25% of patients, requiring systemic therapy that is not always successful. Infliximab is a human-murine monoclonal anti tumor necrosis alpha (TNF-a) antibody. This mediator has a role in the pathogenesis of psoriasis.Aim:
To evaluate the use of infliximab in psoriatic patients resistant to conventional therapies. Material andMethods:
An open prospective study including eight patients with extensive plaque or erythrodermic psoriasis. They were treated with infliximab 5 mg/kg/dose on weeks 0,2 and 6. Patients were evaluated every 2 weeks for a median lapse of 50.1 weeks. Physical examination, PASI scores (Psoriasis Area Severity Index) and a photographic control, were done in each visit.Results:
All the patients responded in the first 10 weeks of follow-up. The mean reduction in PASI score was 86.6%. Six patients received fourth infusion of infliximab at 37.3 weeks, on average. The most common adverse events were pruritus and headache.Conclusions:
This group of patients with extensive plaque or erythrodermic psoriasis resistant to conventional therapies, had a good response to infliximab.
Texto completo:
1
Base de dados:
LILACS
Assunto principal:
Psoríase
/
Fármacos Dermatológicos
/
Anticorpos Monoclonais
Tipo de estudo:
Observational_studies
/
Prognostic_studies
Limite:
Adult
/
Female
/
Humans
/
Male
Idioma:
Es
Revista:
Rev. méd. Chile
Assunto da revista:
MEDICINA
Ano de publicação:
2006
Tipo de documento:
Article
País de afiliação:
Chile